amsacrine and lysine
amsacrine has been researched along with lysine in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| McMahon, J; Nitiss, JL; Vilalta, PM; Wu, H | 1 |
| Jo, K; Topal, MD | 1 |
| Austin, CA; Lakey, JH; Leontiou, C | 1 |
Other Studies
3 other study(ies) available for amsacrine and lysine
| Article | Year |
|---|---|
Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
Topics: Amino Acid Sequence; Amsacrine; Base Sequence; DNA Gyrase; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Glycine; Lysine; Molecular Sequence Data; Mutation; Oligodeoxyribonucleotides; Saccharomyces cerevisiae | 1994 |
Changing a leucine to a lysine residue makes NaeI endonuclease hypersensitive to DNA intercalative drugs.
Topics: Amsacrine; Antineoplastic Agents; Binding Sites; Daunorubicin; Deoxyribonuclease EcoRI; Deoxyribonucleases, Type II Site-Specific; DNA Nucleotidyltransferases; DNA Topoisomerases, Type I; Ellipticines; Enzyme Inhibitors; Integrases; Intercalating Agents; Kinetics; Lysine; Nalidixic Acid; Novobiocin; Oxolinic Acid; Point Mutation; Recombinant Proteins; Recombinases; Topoisomerase I Inhibitors | 1996 |
Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
Topics: Amino Acid Sequence; Amsacrine; Antineoplastic Agents; DNA; DNA Topoisomerases, Type II; Enzyme Stability; Etoposide; Glutamic Acid; Humans; Lysine; Models, Molecular; Mutation; Topoisomerase II Inhibitors; Tranexamic Acid | 2004 |